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Abstract: Among the vast variety of plant-derived phytochemicals, the group of carotenoids has
continuously been investigated in order to optimize their potential application in the area of dietary
intervention related to chronic diseases. One organ that has been especially targeted in many of these
studies and clinical trials is the human prostate. Without doubt, carotenoids (and their endogenous
derivatives—retinoids and apo-carotenoids) are involved in a plethora of intra- and intercellular
signaling, cell growth, and differentiation of prostate tissue. Due to the accumulation of new data on
the role of different carotenoids, such as lycopene (LYC) and β-carotene (BC), in prostatic physiology
and pathology, the present review aimed to cover the past ten years of research in this regard. Data
from experimental studies are presented in the first part of the review, while epidemiological studies
are disclosed in this second part. The objective of this compilation was to emphasize the present
state of knowledge about the most potent molecular targets of carotenoids, as well as to propose
promising carotenoid agents for the prevention and possible treatment of prostatic diseases.
Keywords: beta-carotene; lycopene; metabolism; apo-carotenoids; vitamin A; prostate cancer;
antioxidants, cohort studies
1. Introduction
In the first part of the review [1], we covered the main directions of current investi-
gations targeting the molecular basis of carotenoid actions, summarizing the results of
ongoing research in the field.
This second part of the review is focused on the latest research in the field of associ-
ations of carotenoid intake and/or circulatory concentrations related to the incidence of
malignancy of the most important pathology of prostate—prostate cancer (PC). Today, PC
is the most abundant cancer in men worldwide [2]. In 2018, there were 1,276,106 new cases
diagnosed around the globe, which accounted for 7.1% of total cancer incidence in men.
Consistently, PC was the second most common cancer in American males, constituting
9.5% of all new cases in 2018 [3]. It is still being discussed whether such a high prevalence
of PC is a result of an accumulation of risk factors (especially ageing of society, lack of
physical activity, or improper diet), or whether it is the result of more widely carried out
screening, including for a prostate-specific antigen (PSA). Baade et al. suggested that lower
incidence of PC in certain developed countries could be explained by lesser popularity of
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PSA testing, such as in Japan or Poland [4]. On the other hand, significant differences in the
incidence of PC were noticed according to the ethnicity, for instance 40-fold higher odds
for developing PC among African-American men living in the United States compared to
Asian men living in their native countries [2]. However, the aforementioned risk of PC
tends to be increased in Asian men who migrated to ‘high-risk’ countries.
Presently, the average age of diagnosis of PC is 66 years and the general belief is that
below the age of 50 years its incidence dramatically drops, with only 1 in 350 younger
males being affected by the disease [3].
Since the previous decade, it has been hypothesized that carotenoids (particularly
lycopene (LYC)) might exert a positive influence on the clinical outcomes of PC prophylaxis
and treatment. Although LYC has been shown to improve the incidence and prognosis in
humans and animals regarding gastric, breast, pancreatic, colon, and renal cancer, there
have also been contrasting results reported in this area of research. Additionally, there
is a scarcity of high quality observational and interventional studies performed in order
to unequivocally establish the role of LYC in cancer disease [5,6]. In terms of PC, in 2004,
Etminan et al. conducted a meta-analysis and concluded that adequate intake of tomato
products (i.e., 200 g of tomatoes per day) could visibly reduce the incidence of the disease [7].
Unfortunately, further investigation has not brought any clear conclusion in this regard and,
therefore, it remains one of goals of ongoing research to deliver the proper answer. It is,
however, clear that LYC, among other carotenoids, is a highly bioactive compound with a
multidimensional beneficial role in human health, which has been extensively reviewed [8].
In fact, it is reported to possess the strongest antioxidant properties among all the
carotenoids, which is accomplished by both its ability to directly scavenge reactive oxygen
species (ROS) and to upregulate the antioxidant response elements (ARE) [9]. Therefore,
LYC is capable of reducing tumor cell proliferation, regulating the cell cycle, or inducing
apoptosis of cancer cells [1,9]. LYC seems to exert beneficial effects also in the other fields
of health, especially by acting as a cardioprotective and neuroprotective factor, and by
maintaining skin resistance to photodamage [10].
The main aspects of carotenoids’ physiology and molecular mechanisms of action
have been summarized graphically [1].
The fundamental issue that has hampered previous attempts to define the precise role
of various factors related to PC progression (not only carotenoids) is the fact that the exact
biology of PC itself is still under investigation. In 2015, the team setting up the The Cancer
Genome Atlas proposed a new division of PC into seven molecular subtypes, differing in
their androgen receptor (AR) activity in a subtype-specific manner [11]. In this part of the
review, we try to emphasize our present knowledge of the role of carotenoids in prostate
cancer and prostate-related disease, based on epidemiological studies in humans.
2. Materials and Methods
Here, we provide a brief description of the methodology. A full description of the
methodology was given in part I [1].
2.1. Search Strategy and Study Selection
We have investigated electronic databases (PubMed, Cochrane, Ovid, NICE) in order
to find relevant studies for our literature review. Studies considered included both inter-
vention trials and observational trials determining the association between any carotenoids
and prostate complications. Investigated populations included elderly men with prostate
abnormalities (predominantly PC). For interventional studies, the independent variable
was the amount of supplemented carotenoids or their serum concentration after interven-
tion. Outcomes were assessed as the presence of disease—for PC, measured mainly by
screening tests, PSA, and digital rectal examination (DRE). We decided to extract data from
papers published between the 1st of January 2009 and the 15th of November 2020.
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All received results were manually checked by two authors. The main eligibility
criteria were: studies investigating the impact of any carotenoid on aspects of prostate
physiology and/or pathology.
2.2. Data Extraction
Two authors were chosen to independently find studies, which met the inclusion
criteria. If there were any conflicting situations, a third author was engaged for a final
decision.
2.3. Presentation of Results
An analysis of epidemiological studies was done following the Meta-analysis of
Observational Studies in Epidemiology (MOOSE) standard [12]. However, due to the
strong heterogeneity in their methodology and approaches (as discussed in the following),
we decided that none of the statistical models for meta-analyses would result in appropriate
conclusions and, therefore, we relied on a discussion of unprocessed data from these
studies. To estimate the methodological quality of studies, the Newcastle–Ottawa Scale
was used [13].
The flow chart summarizing the process of data extraction is presented as Figure S1 in
Online Supplementary Material.
3. Carotenoids and Prostate Cancer in Epidemiological Studies
3.1. Carotenoids and Prostate Cancer Risk—Introduction
We identified 23 research articles referring directly to the influence of carotenoids
on PC occurrence. All but one were performed with human subjects. The predominant
investigated carotenoids were LYC (n = 14) and β-carotene (BC) (n = 13). In addition, articles
contained results in relation to retinol (or retinyl esters), α-carotene, β-cryptoxanthin,
zeaxanthin/lutein, phytoene, and phytofluene. Regarding the type of study and its design,
there were 2 controlled clinical trials, 6 cohort studies, 11 case-control studies, and 3 cross-
sectional studies. The largest one was the Health Professionals Follow-up Study, which
presented 5728 PC cases. Basic information about each study (except for the one animal
study) is shown in Table 1. A lot of heterogeneity existed among the results. Four studies
with significant results concluded that carotenoids even increased the risk of PC. Before
taking a closer look at particular studies, we discuss basic factors that appeared to influence
the outcome of the investigations.
Due to the qualitative nature of the analysis, the assessment of risk of bias was done
adhering to the GRADE-CERQual. Following this step, we focused on methodological
limitations, coherence, adequacy of data, and relevance of included studies [14].
1. Number of cases—eight studies included less than 100 cases of PC [15–22] and eight
more than 1000 cases [23–30]. In fact, mainly studies with <100 cases reached statis-
tically significant results. For example, Karppi et al. [15] found in their study that
both α-carotene (AC) and BC significantly increased the risk of PC by about 105% and
129%, respectively (comparing the highest vs. the lowest tertiles of concentrations).
Contrarily, Nordström et al. [20] stated a 69% decrease of PC risk (however there were
no particular concentrations of carotenoids specified, which makes the results of this
study incomparable). These examples demonstrate that especially small-scale studies
may be more prone to diverging outcomes, due to differences in the nature of the
study design, populations included, carotenoid administration schemes, length of
intervention, and many more.
2. Nationality of participants—the nationalities that have been most frequently inves-
tigated are: American (n = 6), Finnish (n = 5), and Italian (n = 2). There were also
Australian, Japanese, and Vietnamese populations. Four studies included multiethnic
groups of participants. The prevalence of PC strongly differed, depending on the
geographic region. According to the Global Cancer Statistics, in northern America,
PC incidence is 73.7 (out of 100,000), 85.7 in northern Europe, 60.7 in southern Europe,
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86.4 in Australia, 13.9 in eastern Asia, 12.7 in southeastern Asia, and 64.1 in southern
Africa (age-standardized rate per 100,000) [31]. It is possible that the susceptibility
to carotenoids depends on specific configurations of genetic polymorphisms, but
influences regarding lifespan, pollution, and other factors, such as sun exposure
etc., may also likely play a role. Moreover, such associations between genetics and
environmental factors have been already suggested and shown (e.g., for TMPRSS2:
ERG) [22]. Other factors confounding the distribution of PC are access to medical care,
physical activity, dietary habits, and addictions—factors that are also strongly related
to the country of investigation. For example, in a Vietnamese study by Van Hoang
et al. [32], which took place from 2013 to 2015, it was suggested that results should
be interpreted carefully for the Vietnam population, as only the Ho Chi Minh City
population was investigated. Accordingly, conclusions should be rather restricted to
the investigated populations instead of trying to generalize them.
3. Evaluation of outcome—this is probably the most confusing factor explaining the
high level of inconsistency among results of different studies. First, none of the
prospective studies could guarantee that the outcome—PC development—was not
present at the beginning of study. For example, the two included controlled clinical
trials [23,33] extracted data about diagnosis from corresponding cancer registries.
However, this solution has two great disadvantages. Diagnosis of PC is indicated by
raised PSA levels or pathological findings in DREs. Lower urinary tract symptoms
could lead to diagnosis as well. If there are none of these indications, PC would
remain undiscovered. None of the studies began by a diagnostic biopsy to exclude
the presence of PC before an intervention. It is understood that starting research
with invasive procedures is a large technical and ethical difficulty and could not be
achieved—it should be merely stressed that among people aged 50–69 years (the
dominating group in the conducted studies), there is a significant chance to find
clinically silent, developing PC. The mean age of PC diagnosis in the US is 66, but
average time of tumor growth is estimated as 10 years [2].
In turn, there is one important example of how post-research evaluation is likewise
important, as presented by Kristal et al. [26]. During their Prostate Cancer Prevention
Trial (PCPT) study, which lasted for nine years, 772 cases of PC were found. At the end of
the study, all participants underwent a “not-for cause biopsy” (while “for cause biopsy”
means one indicated by PSA or DRE screening, or lower urinary tract symptoms). From
this, 911 cases of PC were revealed, which constituted 54.1% of all cases. This strongly
suggested that underdiagnosing of PC could contribute to a large diagnostic bias (there has
been no other study that introduced the idea of a “not-for cause biopsy”). As the outcome
assessment of all studies might have been altered by such additional measurements, we
should pay particular attention to the borderline results (both positive and negative).
4. Evaluation of carotenoids—there were three main methods used for calculating a
relationship between PC incidence and carotenoids: (a) patients were given sup-
plements containing a known quantity of carotenoids [18,23]; (b) carotenoid con-
centration in serum was measured [15–17,19,20,25–28,30,33,34]; and (c) carotenoid
intake was estimated according to the results of standardized food frequency ques-
tionnaires [21,22,24,29,32,35]. Serum concentrations of carotenoids are considered
to be correlated with PC in a more direct way than dietary intake [26], despite both
being correlated [36]. Despite this, investigating the intake of carotenoid-rich food
items is still paramount, especially for the health care system. It could offer a simple
strategy for primary prevention of the disease, whereas laboratory analysis could
support a further diagnosis instead. Additionally, proper calibration and adjustment
for dietary habits seems plausible to reduce the risk of bias, as it was done in the latest
Adventists Health Study-2 [29].
5. Studies that tested supplementation of carotenoids did not evaluate carotenoid dietary
intake in any way. For example, in the CARET study, the only limitation for a
participant was not to use dietary supplements containing >5500 IU/day retinol or
Antioxidants 2021, 10, 319 5 of 26
any BC [21]. However, no evaluation of dietary habits was carried out. Therefore, a
large bias due to the differences in daily intake of red and yellow vegetables (especially
carrot, rich in BC) must be considered here. The same is true for the ATBC Study [23]
and the Procomb trial [18].
6. Measurement of serum concentrations of carotenoids was the predominant method
in the investigated studies (11 of 22). However, the course of the procedure of
taking blood samples varied strongly among different studies. Only in the KIHD
study was the procedure precisely described, which included: (i) definition of times
for taking blood samples (between 8:00 AM and 10:00), (ii) definition of the site of
sampling (antecubital vein), (iii) presampling recommendations for patients (to be
after overnight fast, abstain from consuming alcohol for 3 days and from smoking for
12 days), (iv) definition of the technique for taking blood samples (blood sample was
taken without tourniquet and after 30 min of resting in supine position) [15,16]. None
of these aspects were discussed in nine studies [19,20,25–28,33,34] and only one aspect
was mentioned in one study [17]. In different studies, the blood was taken into either
heparinized tubes, EDTA-tubes, or tubes without anticoagulant. The influence of
methodology of taking blood sample on measuring carotenoids was not investigated
in any research. Therefore, the magnitude of potential bias from such diverging blood
drawing techniques remains unknown.
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Table 1. Studies that investigated the role of carotenoids in the prevention of prostate cancer (PC). The OR refers to the odds of developing PC when comparing the intervention group to a
control group (in controlled clinical trials) or the group with minimal to the group with maximal carotenoid concentration.
Study Type
Study Name (If
Given) and the First
Author






[RR or HR, or OR
(95% CI)] 1





3 322 BC + retinyl ester 11 years 30 mg + 25,000 IUper day N/C 0.65 (0.43, 0.97) - All participants were smokers [21]
ATBC Study
Virtamo 2014 Finnish 2321 BC 18 years 20 mg per day N/C 0.98 (0.88, 1.10) - All participants were smokers [23]
Cohort study
KIHD
Karppi 2009 Finnish 55 LYC 12.6 years <4.3 µg/dL >10.2 µg/dL p >> 0.05 8 - [16]
ATBC Study
Mondul 2011 Finnish 1732
BC
Retinol 3 years
20 mg per day
<48.3 µg/dL
-
>68.5 µg/dL 1.19 (1.03, 1.36) 8 All participants were smokers [25]
KIHD




















Umesawa 2014 Japanese 143
BC
AC 16 years
<0.986 mg per day
<0.105 mg per day
>3.178 mg per day
>0.496 mg per day
p >> 0.05
p >> 0.05 8 - [35]
HPFS
Zu 2014 American
3 5728 LYC >10 years <36.6 µg/dL >50.2 µg/dL 0.91 (0.84, 1.00) 8 For pre-PSA era:0.88 (0.79–0.98) [37]
HPFS
Graff 2016 American
3 884 LYC >10 years <3.861 mg per day >10.262 mg per day 0.88 (0.81, 0.96) 8 For ERG (+) PC: 0.52 (0.37–0.73) [22]
ATBC Study




Canadian 1226 LYC 7.9 years 6.3 mg per day
4 5.9 mg per day 4 p >> 0.05 8
No smokers
HR for canned or





3 692 Retinol 8 years 28.0–54.0 µg/dL 85.0–263.0 µg/dL 0.52 (0.32, 0.84) 9 Results only for Gleason ≥ 7 [33]
MEC






























- p >> 0.05 5 Study does not allow to estimate
β-carotene intake [24]














5 All participants were smokers orexposed to blue asbestos [17]
PCPT
Kristal 2011 multiethnic 1683 LYC 7 years <26.3 µg/dL >46.6 µg/dL 1.42 (1.03, 1.96) 9 Only in “not for cause” group [26]
ProtecT
Gilbert 2012 English 1433 Retinol 4.4 years 14.3–40.1 µg/dL 63.0–117.44 µg/dL p >> 0.05 7 - [27]




Given) and the First
Author






[RR or HR, or OR
(95% CI)] 1
Quality 2 Comments Reference
PCPT















T: p >> 0.05
A: 1.32 (1.01, 1.73)
T: 1.30 (1.00, 1.68)
A: 1.74 (1.14, 2.68)
p >> 0.05
9 T for “total PC”A for “aggressive PC” [34]
Procomb
Morgia 2017 Italian 9 LYC (+ Se) 2 years 5 mg per day - p >> 0.05 8 - [18]







<3920 mg per day
<743 mg per day
<648 mg per day
<539 mg per day
<1670 mg per day
>5780 mg per day
>976 mg per day
>1200 mg per day
>867 mg per day



































- Results refer to PSA level, not PCincidence [28]
Mariani 2014 Italian 9 LYC N/C <1 ng/mg >1 ng/mg not given - LYC concentration was measuredin prostate biopsy specimen [19]









1 Relative risk in all clinical controlled trials, hazard ratio in all cohort trials, and odds ratio in all case-control studies and cross-sectional studies. 2 According to the Newcastle–Ottawa Scale. 3 The mentioned
nationality was most prevalent in the given study. 4 Estimates for participants with no PC vs. with any type of PC, respectively. Abbreviations: AC—α-carotene; AHS-2—Adventist Health Study-2; ATBC
Study—The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; BC—β-carotene, CARET—The Beta-Carotene and Retinol Efficacy Trial; HPFS—Health Professionals Follow-Up Study; JACC—The
Japan Collaborative Cohort Study; KIHD Study—The Kuopio Ischaemic Heart Disease Risk Factor Study; LYC—lycopene; MEC—multiethnic cohort; NHANES—National Health and Nutrition Examination
Survey; PC—prostate cancer; PCPT—Prostate Cancer Prevention Trial; PLCO—Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; ProtecT Trial—Prostate Testing for Cancer and Treatment Trial;
PSA—prostate-specific antigen.
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Indeed, serum concentrations of carotenoids may differ strongly depending on the
time of sampling. Among the analyzed studies, in four of them, more than one single
sampling of blood was carried out [19,26,33,34]. Findings from the PCPT study suggest
that a single measurement may not be sufficient for establishing a correlation to future
serum carotenoid concentrations. Intraclass correlations for a given carotenoid in serum
concentration over seven years were: BC 46.3%, retinol 64.2%, α-carotene 73.7%, and
β-cryptoxanthin 78.7% [34]. To compare, in the ATBC study, correlation between baseline
and three-year retinol measurements was 80.1% [25]. It has already been shown that
the concentration of carotenoids depends, among others, on the season of year. A good
example is a more than 100% higher serum retinol concentration in mobile pastoralists
in Chad when sampling was taken in the rainy season, compared to the cold season [39].
This variability strongly lowers the accuracy of a single measurement for predicting later
carotenoid concentration within-subjects, with the most significant impact on assessment
of BC and retinol.
The least heterogeneity among studies was observed regarding the methodology
of laboratory analyses. The single and only method used was high performance liquid
chromatography (HPLC), as this is the routine technique for carotenoid detection and
quantification, though also HPLC coupled with mass spectrometry (LC-MS) is becoming
more common [40–42], especially for determining carotenoid metabolites. In brief, serum
samples are stored at low temperature (−70 ◦C or −80 ◦C) until the moment of analysis.
Then, they are extracted with hexane (sometimes ethanol, though this would not extract
the more apolar carotenoids) and the sample is evaporated and then re-dissolved in mobile
phase (often acetonitrile–methanol–chloroform mixtures). Next, samples are injected onto
a C18 (or C30) analytical reversed phase column and detected by diode array detector.
Routine wavelengths used are: for LYC 470 nm, for AC and BC 452–454 nm, for retinol
325 nm, and for β-cryptoxanthin 476 nm [15,16,20,25,26,28,34]. The quantification occurs
typically via external calibration curves, employing commercially available standards,
though internal standards such as trans-beta-apo-8′-carotenal are also used [40,41].
7. Studies that investigated the effects of dietary carotenoids used a slightly different
way to assess their results. In the Health Professionals Follow-up Study (HPFS)
study, data collection was conducted through a standardized 131-food-item semi-
quantitative Food Frequency Questionnaire (FFQ). Respondents were obliged to fill
out the questionnaire a total of six times to eliminate the influence of dietary habit
changes during the twenty-year-long study period. Questions about frequency and
type of consumed food were asked. This is an often used technique for estimating
the daily intake of carotenoid-rich food items. The content of each carotenoid was
then calculated by means of data from the US Department of Agriculture (USDA)
food composition database [21,22], which is one of the few databases with sufficient
entries regarding carotenoid content, i.e., listing various food compounds and their
carotenoid profile and amount per food item. The study conducted by van Hoang
et al. in Vietnam used data from the USDA database as well, but they applied
only a 89-item questionnaire [32]. In the Japanese JACC study, only 35 foods were
investigated. Additionally, not all of them were considered as frequently eaten in
other countries (i.e., Chinese cabbage or garland chrysanthemum) [35]. This makes
the results of the discussed studies less comparable, apart from the limitation of
using food composition databases from other countries, as food composition is much
influenced by provenience and other aspects, such as storage and processing of food
items. Each of those studies were tailored toward different populations, and results
should not be expanded to others.
8. The overall quality of studies was high or moderate. Controlled clinical trials [21,23]
provided strictly defined intervention and control definitions as well as the endpoint.
The blinding process was conducted in the proper way. The main concern is the lack
of data regarding the concealment of allocation. Issues regarding assessment of the
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carotenoid intake or technique of diagnostic material acquisition were discussed in
previous paragraphs.
All cohort studies [15,16,22,25,29,30,35,37] received 8 of 9 Newcastle–Ottawa Scale
(NOS) points, as they were not able to exclude the presence of the endpoint at the beginning
of the study (i.e., none of the study involved initial prostate biopsy to exclude presence of
clinically silent PC). Nevertheless, the remaining NOS criteria were excellent met.
Among case-control studies, some received lower scores according to NOS scale be-
cause: the exclusion of PC in the control group was not done, the control population was
selected from a specific group (i.e., patients with cardiovascular diseases), the exposure as-
sessment was poor (i.e., the questionnaire was not standardized and validated) or they were
lacking information about blinding to case/control status of interviewer, or the information
about nonresponse rate was not provided. Therefore, four case-control studies [17,24,27,32]
received 5–7 NOS point and their quality must be considered as moderate.
No major concerns regarding the quality of cross-sectional studies were raised—
whether it must be taken into consideration, that their results could be only supportive in
any sort of concluding about the relationship between carotenoids and PC incidence.
In the following, we discuss results of our findings separately for LYC, BC, and retinol.
This approach was due to the different biology and absorption distribution, metabolism,
and excretion (ADME) of each carotenoid. Indeed, their effects were reported to be either
different or even antagonistic.
3.2. Carotenoids and Prostate Cancer Risk—Lycopene
Before focusing on the human studies, we will first discuss the one animal study that
was dedicated to analyzing the risk of PC. It drew some conclusions that appear to be
important for a better understanding of results and restrictions of the human studies. The
study was conducted by Conlon et al. in 2015 and investigated whether supplementing, in
a TRAMP mice model, with 10% tomato powder (TP), would influence the incidence of PC.
The duration of the intervention was eight weeks. In this study, the effects of LYC and BC
were examined. The only results that reached significance were inconsistent with the time
trend—LYC was shown to reduce the risk of adenocarcinoma after sixteen weeks, but not
in groups of mice after twelve or twenty weeks. Another finding of this research was more
indicative. The tissue of distribution of carotenoids differed strongly and depended on
serum carotenoid concentrations in a nonspecified way. For LYC, the liver concentration
was almost linearly related to serum concentration. For gonadal adipose tissue, there was a
trend found. Finally, in testes and anterior prostate (equivalent to the human prostate), LYC
concentrations were constant regardless of the changes in serum concentrations. BC was
not measured in tissues due to its low levels (below the limit of detection—0.5 nmol/g) [43],
which is typical for mice having a much higher BCO1 activity than humans. The results
questioned whether serum concentrations of LYC are a good revelator of its presence in
prostatic tissue, though this was claimed in some human trials [36,44].
Among the 13 human studies investigating LYC (five cohort [15,16,22,29,37], five
case-control [17,18,26,32,38], and three cross-sectional studies [19,20,28]), six presented
statistically significant results [21,22,26,29,32,37]. There were three prospective studies,
and two based their conclusion on the results of the HPFS, published in 2014 [21] and
2016 [22], while the remaining study was the AHS-2 [29]. In this study, the investigated
cohort consisted of 48,898 male health professionals aged between 40 and 75 years at
baseline. More than 90% of participants were white Americans, and a total of 5728 PC cases
were followed. In a study conducted by Zu et al., LYC intake was presented according to
quintiles (Q1: <3.687 mg per day; Q5: >10.131 mg per day). For the highest quintile, there
was a borderline protective effect against total PC—HR, which was 0.91 (95% CI: 0.94, 1.00).
The unique feature of this research was that the authors investigated differences of LYC
in the pre- and post-PSA era. It was intended to check whether the effectiveness of LYC
was modulated by primary prevention. Among men who underwent at least one negative
PSA test at baseline, the HR for the fifth quintile was 0.88 (95% CI: 0.79, 0.98). The team
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concluded that high dietary LYC intake was associated mainly with a reduction in the
more aggressive states of the disease, which resulted in stronger clinical symptoms. They
supported the idea of additional measurements of vessel development and angiogenic
marker expression in collected tumor tissue. The angiogenic score was significantly lower
in the lowest quintile compared to the highest (Q1: −0.32; Q5: 0.12; p < 0.0007) [37].
Results of the HPFS study were also investigated by Graff et al., especially in the context of
molecular subtypes of PC. The tumor with the fusion gene TMPRSS2: ERG is said to be
present in about half of all PC cases worldwide and contributes to the development of PC.
The authors verified whether this specific translocation influenced cancer susceptibility to
LYC. The quantile ranges were very similar to the ones described above (Q1: <3.861 mg per
day; Q5: >10.262 mg per day). Among the 5543 PC cases, 884 were assayed for ERG. For
the last quintile, there was a similar protective effect, with an HR of 0.88 (95% CI: 0.81, 0.96).
Finally, the ERG (+) PC weighted HR was 0.52 (95% CI: 0.37, 0.73) and protective effects
were seen starting from the third quintile. This study proposed that LYC protected from PC
more in the pre-PSA era, as HRs for each parameter in a cumulative average model were
slightly higher than in the baseline analysis (HPFS was run in 1986, while using PSA as
primary prevention method started in 1994). The authors suggested that a more significant
reduction in ERG (+) PC incidence could explain the results of some previous studies,
which showed no association for LYC. In Asian populations the prevalence of TMPRSS2:
ERG translocation is less frequent, so studies that investigated Asiatic populations may not
have found such a strong reverse correlation [22].
The newest report touching on the issue of tomato intake (though, indirectly of LYC)
is AHS-2, covering the cohort of 27,934 men and 1226 PC cases from America and Canada,
who were followed-up with over 7.9 years. The study was based upon FFQ questionnaires
used to estimate daily LYC intake (with particular attendance referred to tomatoes and
tomato-based products). The mean LYC intake was 6.1 mg per day in men without PC and
5.8 mg in those who developed PC of any severity (p = 0.174, none of the further mentioned
variables were significant for this comparison). However, considering the intake of LYC
derived only from canned or cooked tomatoes (0.726 mg vs. 0.625 mg of LYC, or 25.0 g
vs. 21.5 g of tomatoes per day, respectively), a strong protective effect against PC was
revealed (calibrated HR = 0.38 (95% CI: 0.07, 0.97), and distinctly so for the aggressive
disease in the age-adjusted model (Gleason score ≥ 7; HR = 0.83 (95% CI: 0.69, 0.99), but
not significantly in the multiadjusted model). The study introduced the interesting idea
that the processing of LYC-containing products might in fact enhance its capability to limit
the growth of PC. The authors’ suggestion was that the observed effect stems from an
increased bioavailability of a heated or oil-treated LYC-rich matrix (due to the increase
of its cis-isoforms, predominant in human blood and tissues, which may be of higher
bioavailability than the all-trans form) [29].
Results of the HPFS study showed that dietary LYC was associated with a protection
from developing PC. Results were adjusted for almost all confounding factors that could be
interfering (i.e., age, nationality, physical activity, addictions, and smoking)—only alcohol
intake was not included. The analyzed groups were the largest ones of those included in
the present review. Also, the dietary questionnaires were taken six times, thus the changes
in nutritional habits were closely monitored. The main concern was that all participants
were healthcare professionals and, therefore, might not be a representative group of the
whole community. Analysis for TMPRSS2: ERG associations was naturally limited only to
subjects who underwent a radical prostatectomy, as this specific translocation is acquired
in prostatic tissue, while dysplastic changes are further developing. It is worth noting
that a reverse association with PC was even stronger for tomato sauce than for LYC alone,
as shown by Graff et al. [22]. As the LYC intake itself was calculated only based on FFQ
results, it could be theoretically possible to overestimate the influence of LYC, assuming
there are other protective agents in food, such as dietary fiber, polyphenols, vitamin E,
or other. On the other hand, it is possible that LYC absorption and metabolism is merely
supported by other active compounds present in vegetables and vegetable-based food
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items. One needs to consider also the food processing, which, according to the results of
the AHS-2 study, are a crucial factor determining results of dietary LYC [29]. Data obtained
from such studies may be of particularly practical potential, as they could be translated
more directly into dietary recommendations.
Out of the three retrospective studies, one found a positive correlation between LYC
and PC, however it still referred only to one specific type of PC—detected despite any
indication by biopsy (the PSA level and DRE were normal). It was based on results from
the Prostate Cancer Prevention Trial (PCPT), which originally tested the efficacy of 5 mg
per day of finasteride, an 5-α-reductase type 2 inhibitor, for PC prevention. The study
assessed LYC serum concentrations but also included prostate biopsies collected every year,
which enabled researchers to avoid bias due to the PSA-dependent underdiagnosis of the
disease. Almost 90% of cases were white Americans, thus the ethnic structure was similar
to that of the HPFS study. LYC concentrations were stratified by quartiles (Q1: <26.3 µg/dL;
Q4: >46.6 µg/dL). In the placebo arm, the only statistically significant result was a higher
risk of PC not found by PSA screening in the fourth quartile—HR was 1.42 (95% CI:1.03,
1.96). Interestingly, in the finasteride arm, the frequency of PC detected due to the raised
PSA was lowered; HR was 0.57 (95% CI: 0.34, 0.95). Simultaneously, if already diagnosed
for cause, the disease was more aggressive and presented a higher grade or stage. There
were about 50% more cases of PC in Gleason stages 7–10 in the for cause group than in the
not for cause group [26].
In a somewhat disturbing conclusion, it was thought that the protective effect of LYC
might merely be due to lowering the sensitivity of the PC screening instead. Not-for-cause-
detected tumors in PCPT comprised 46.8% of the total cases. In the highest quartiles of
LYC, the quotient of risks of not for cause/for cause were increasing strongly. It cannot be
compared to any other study, as prostate biopsies have not been used commonly in studies.
It is possible that LYC could, in fact, impair detection of a low-grade disease, which would
not turn out to be harmful even in long-term perspective.
Another case-control study was carried out in Vietnam by van Hoang et al. in 2013-
2015 [32]. Within this study, data about dietary habits of citizens of Ho Chi Minh city
were collected, using the information to calculate average LYC intake. The FFQ used in
this study was comprised of 89 food items—it is worth underlining that tomato sauce
(found as the most effective source of LYC in the aforementioned studies) was excluded
from that questionnaire as it is not popular in the Vietnamese population. The population
studied comprised men aged 64–75 years. Among the 652 participants, 244 PC cases were
described. Results were presented as tertiles (Q1: <0.648 mg per day; Q3: >1.2 mg per
day). It is an interesting observation that, despite the fact that the highest tertile had a
three-times lower risk than the lowest in HPFS, the protective effect of LYC remained
significant and strong here. The value of OR for the third tertile was 0.46 (95% CI: 0.27,
0.77). For tomatoes, there was an observed 61% reduction of PC risk in the third tertile. It
also turned out that all protective effects contributed to the low grade disease, as for PC
with a Gleason score ≤ 7, OR was 0.41 (95% CI: 0.21, 0.77) and no correlation was shown
for the aggressive disease.
Despite the results being generally in agreement with the findings of the HPFS, there
are some differences that impede the comparison of their conclusions. First, the Vietnamese
study was retrospective and, in addition, data were extracted from the population of a
single city. There were also significant changes between the questionnaires (e.g., exclusion
of tomato sauce) compared to the HPSF. Interestingly, this study put into a question the
assumption that in Asiatic populations the effect of tomatoes and diets high-in-lycopene is
weaker than in American or European populations. Given that the intake of carotenoids in
this study was much lower than in American studies, it may even suggest some U-shaped
curve of dependency. The narrow range of the study allows us only to state that LYC might
protect from low-grade PC in the Vietnamese population.
The last study of LYC was the North Carolina–Louisiana Prostate Cancer Project
(PCaP), a cross-sectional study investigating, separately, the role of LYC in European
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Americans (EA) and African Americans (AA), aged 40–79 years. Dietary habits were col-
lected based on the National Cancer Institute’s Diet History Food-Frequency questionnaire
(NCI-DHQ), containing 144 common food items. Additionally, data about carotenoid
supplement intake were taken. Results were presented as tertiles (Q1: <3.605 mg per
day; Q3: >6.299 mg per day). In this study, there was a protective effect of LYC against
aggressive PC (defined as Gleason ≥ 8) and the OR for the third tertile was 0.55 (0.34,
0.89). However, it referred only to the EA group; as for the AA, they found no significant
associations [45]. Due to the cross-sectional character of the study, we could only conclude
that EA people with diagnosed high-grade PC had a lower dietary intake of LYC at the
time of cancer diagnosis.
When summarizing our conclusion for LYC it can be stipulated that:
1. Increased consumption of LYC from canned or cooked tomatoes might be related to
a reduced hazard of developing PC (e.g., 25 g vs. 20 g per day of tomatoes reduces
hazard by ~60%) and, supposing, aggressive PC;
2. Intake of more than 10 mg of LYC was related to a reduced risk of diagnosing PC, by
at least 10%, compared to an intake below 3.6 mg per day in European and American
populations;
3. For men with TMPRSS2: ERG translocation, the reduction in risk of diagnosing PC
reached about 50%;
4. LYC was associated with an increased risk of developing PC without abnormal PSA
or DRE by about 40%—however, this subgroup of PC is actually undetectable (by
definition) due to the lack of clinical signs;
5. The clinical significance of underdiagnosed PC cases must be evaluated—if they
remain unharmful over time, it would be beneficial from a public health point of view
not to detect their presence—reducing the postoperational burden of patients and
costs of healthcare;
6. In the Vietnamese population, an intake of 1.2 mg of LYC per day was associated with
a reduced risk of diagnosing PC by about 50% compared to a daily intake of less than
0.648 mg.
3.3. Carotenoids and Prostate Cancer Risk—BC
There have been twelve studies that focused on BC. However, their comparability is
low. Two were cross-sectional [20,28], five were case-control [17,24,32,34,38], three were
cohort studies [15,35,38], and two were intervention trials [21,23]. Firstly, we will discuss
the Carotene and Retinol Efficacy Trial (CARET) and the Alpha Tocopherol, Beta Carotene
Cancer Prevention Study (ATBC) as they were both rather clinical-controlled intervention
trials. In CARET, participants were supplemented with 30 mg of BC and 25,000 IU of
retinyl palmitate every day for an average of 11 years. In this study, a total of 890 PC cases
were reported. It must be highlighted that all participants of the study were smokers or
exposed to asbestos in the past. There was a subgroup of participants who additionally took
commercial dietary supplements. The results were presented separately for the intervention
and postinterventional phase (follow-up) of the study. Significance was reached only for
the intervention part. For the active study arm without supplements, RR for nonaggressive
(but not total) PC was 0.65 (95% CI: 0.43, 0.97), compared to placebo without supplements.
In the active arm of the study there was a slightly higher prevalence of high-grade PC
(Gleason score ≥ 7) in comparison to the placebo group (44.6% versus 40.1%) [33]. In the
ATBC study, Finnish men, aged 50–69, received 20 mg of BC daily for an average of six years
(the group that was supplied only with tocopherol will not be discussed here). In total, 2321
cases of PC were evaluated. Again, in this study all subjects were smokers. This study did
not show any significant correlation between BC and PC as the RR was 1.03 (95% CI: 0.95,
1.12). The post-trial analysis also showed no associations [23]. Both of these prospective
studies referred only to excessive smokers (people who smoked around 20 cigarettes a
day). On the one hand, the protective effects shown in CARET may be due to the higher
dosage of BC than those used in the ATBC study. On the other hand, the effects of retinyl
Antioxidants 2021, 10, 319 13 of 26
esters should likewise not be underestimated. As the protective effect disappeared in the
follow-up, it may be proposed that only continuing extensive supplementation with BC
and retinyl palmitate lowered the risk of PC.
Another large-scale study also investigating the Finnish population was The Kuopio
Ischaemic Heart Disease Risk Factor Study (KIHD). This trial evaluated serum levels of BC
in patients aged 42–60 years at baseline. The second measure was taken at the end of the
study. Mean concentrations were divided into tertiles (Q1: <13.4 µg/dL; Q3: >21.5 µg/dL).
This was the only study that provided full data on the blood sampling procedure, which
allowed us to largely exclude diagnostic bias in this study. A total of 68 PC cases were
registered. In this study, cases were significantly older than those without PC—means for
age were 58.9 and 55.9, respectively (p < 0.001). Among these cases, significantly higher
concentrations of α-linoleic (ALA) were observed, which was meant to be a covariate for
results (elevated in PC cases). The difference in plasma BC levels was also significant,
although less remarkably. Mean concentrations were 24.7 and 20.4 µg/dL, respectively
(p < 0.04), however BC concentration varied, depending on the month of sampling, with
highest concentrations between July and September. This study observed a great increase
in PC risk for higher BC concentrations. The RR for the third tertile in comparison to
the first was 2.29 (95% CI: 1.12, 4.66) in a fully adjusted model (adjustment covered age,
examination year, family history of cancer (yes vs. no), BMI, years of smoking, alcohol
consumption, education, physical activity, serum total cholesterol, and serum ALA) [15].
This nested case-control study should be carefully considered. The small sample size, a few
factors that differed between cases, and unaffected participants suggests some risk of bias.
In addition, the whole group was from one city, and thus they might not be representative
for the general Finnish community. Finally, seasonal and personal fluctuations in BC levels
seemed to be a possible confounder in such a small trial.
The fourth study was conducted by Nordström et al. and analyzed circulating
carotenoids, PC risk, and their relation to the genomic instability in a population of 81
Caucasian men. The concentrations were given in quartiles. In total, 20 of the SNPs in
SOD1-3, XRCC1 and OGG1 genes were measured. In this study, men with high-grade
tumor (Gleason score ≥ 7) were preferably chosen. Comparing the highest versus the
lowest quartile, OR for diagnosis of a high grade of PC was 0.31 (95% CI: 0.15, 0.63) in the
fully adjusted model (adjustment for age at diagnosis (years) and circulating cholesterol
(mg/dL), smoking status at diagnosis (ever vs. never), and Caucasian origin). It is worth
noting that nonadjustment for smoking resulted in both higher OR value and a lower
p-value—suggesting again an inverse association between BC and cigarettes. Interaction
with SNPs turned out to be beneficial for the TC/CC genotype of rs699473 in the SOD3
gene. The OR value for the risk of high grade PC in Q4 versus Q1 among TC/CC genotype
carriers was 0.20 (95% CI: 0.09–0.45) [20]. This study undoubtedly introduced the idea of
strongly differentiated molecular susceptibility to carotenoids, especially to BC. This may
raise caution for highlighting the results of this study due to the lack of presenting quartile
ranges used in analysis.
In summary, none of the prospective studies met the requirements to be used as a
source of any strict conclusions (e.g., due to the subjects being nonrepresentative for the
whole community). Simultaneously, the study by Nordström et al. comprised not enough
cases and its retrospective character could be a source of bias. Based on the collected data,
we can only derive certain partial conclusions:
1. In smokers, constant supplementing 30 mg of BC (together with 25,000 IU retinyl
palmitate) each day may decrease the risk of developing nonaggressive PC;
2. Maintaining a higher serum BC level might decrease the risk of high grade PC,
particularly among people with the TC/CC variant (rs699473) in the SOD3 gene. On one
hand, SOD3 plays a significant role in ROS handling. On the other hand, free radicals react
easily with BC. It could provide an explanation for the correlation of SOD3 polymorphisms
to protective effects of BC.
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3.4. Carotenoids and Prostate Cancer Risk—Retinol and Retinyl Esters
Nine studies included in our review evaluated the effectiveness of retinol toward the
prevention of PC. These included one cross-sectional [28], five case-control [27,28,30,33,34],
and three cohort studies [15,25,30]. Four of them reached a statistically significant out-
come. The placebo-controlled trial, CARET, which investigated effects of long-term sup-
plementation of retinyl palmitate together with BC, was described and discussed in the
previous chapter.
Three case-control studies referring to serum concentration of retinol were nested
in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) within
the ATBC study and in the PCPT. The PLCO involved 692 cases of PC (cases of non-
Hispanic Black men were excluded from analysis). Concentrations were given in quintiles
(Q1: 27.4–54.7 µg/dL; Q5: 85.4–262.6 µg/dL). Statistically significant results were found
for risk of high-grade disease (Gleason score ≥ 7) in Q1 versus Q5, with an OR of 0.52
(0.32, 0.84). For each quintile, a protective effect was shown (compared to the first one). A
correlation with clinically aggressive disease stage (III or IV) could not be demonstrated.
What weakens the impact of the results from this study is that retinol concentration
was measured only once, at the baseline of the study. For a small subgroup of 46 men,
assessment was repeated one year after baseline and only a moderate correlation with initial
retinol concentration was found (r = 0.38) [33]. The ATBC study design has been described
in the previous section. In this nested case-control study by Mondul et al., baseline and
three-year serum retinol were measured. In total, 1732 cases of PC in Finnish smokers
supplemented with a daily dose of 20 mg of BC were collected. During the three-year
course, correlation of retinol concentrations were 80.1% between the baseline and three-year
measurement. The results were given in quintiles (Q1: <48.3 µg/dL; Q5: >68.5 µg/dL). The
highest concentration of retinol was associated with a higher risk of total PC, both for the
baseline and three-year follow-up. HRs were 1.19 (95% CI: 1.03, 1.36) and 1.22 (95% CI: 1.05,
1.41), respectively. The authors of the study emphasized that although all participants of the
ATBC study were smokers, adjusting for pack-years, the duration of smoking or number of
cigarettes smoked every day did not change this outcome significantly [25]. These results
were also obtained following a reanalysis by Hada et al. in 2020, who concluded that HRs
were actually higher after adjustment for multiple variables (HR = 1.28 (95% CI: 1.13, 1.45)
p < 0.0001). In fact, exclusion of participants diagnosed within two years of blood sample
collection (i.e., reducing the risk of bias due to the diagnosis of already developing PC at
the initial point of the study) slightly increased HR [30].
The PCPT design was also described in the previous chapter. In this investigation
by Nash et al., a positive association of serum retinol and aggressive PC was shown. At
the end of the study, all participants underwent prostate biopsy, resulting in 54.1% of total
PC cases. Measurements of retinol concentrations were done annually. Average results
were given as quartiles (Q1: <58 µg/dL; Q4: >77 µg/dL). An increased risk of total PCa,
as well as aggressive disease (Gleason score ≥ 7), was shown—ORs (Q1 versus Q4) were
1.43 (95% CI: 1.02, 2.01) and 1.91 (95% CI: 1.10, 3.31) respectively. Moreover, results were
stratified depending on whether PC was detected for cause (indicated by DRE or PSA) or
not for cause. The highest serum retinol levels resulted in a 145% increased incidence of
aggressive PCa (95% CI was 1.24, 4.85). All these associations were seen only in the placebo
arm of the PCPT (men who had not been receiving finasteride) [34]. As it was previously
discussed, in the PCPT, it was shown that LYC increased the risk of clinically undetectable
PC, particularly the nonaggressive disease. For retinol, somehow contrasting results were
found—an increased risk of high-grade PC diagnosed for cause. This led to the hypothesis
that different carotenoids may not so much affect the risk of PC itself but rather modifying
the chance to detect the tumor, through interfering with, for example, concentrations of
PSA. The NHANES study investigated the influence of retinol on PSA level, however it
did not reach any significant result in a fully adjusted model [28].
It is of high importance to mention the discoveries of novel research conducted with
participants of the PLCO study (4662 cases and 3114 controls—substantially more than in
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previously published results from this trial). From 31 investigated genes involved in retinol
metabolism (most of which were discussed in the part I of this review [1]) SNPs of two
genes were significantly more frequent in patients with PC, namely rs1330286 of ALDH1A1
(OR = 0.88, 95% CI: 0.83, 0.94; the expression quantitative trait loci (eQTL) of this gene) and
rs4646653 of ALDH1A3 (OR = 1.17, 95% CI: 1.07, 1.27), with increased ALDH1A3 mRNA
in PC tissue specimens than in healthy controls [46]. For years considered as the marker
of PC stem cells, now ALDH1A1 gains interest as the link between retinol and PC. This is
supported by results of laboratory investigations—e.g., its inhibition by sylibin resulted
in reduction of RARα in DU-145 cells and prevention of proliferation, migration, and
invasion [47]. The frequency of ALDH1A1 polymorphism was equal to 45% in PC group.
Thus, there are not sufficient data to develop a strict conclusion on the effectiveness of
retinol regarding the prevention of PC. Referring to the results of the PLCO and the ATBC
trials it could be stated that:
1. In smoking subjects with high retinol serum concentrations, there is a 20–30%
increased risk of total PC;
2. Retinol might increase the risk of detecting high-grade PC, but it is uncertain
whether it increases the growth of tumor (unfavorable effect), whether it merely causes
increases in PSA concentrations, or enables a more sufficient primary prevention (beneficial
effect).
3.5. Carotenoids and PC Risk—General Conclusions
The relationship between carotenoids and PC appears heterogeneous and complex.
Results of the largest, prospective trials suggest that dietary LYC is protective against PC.
For other carotenoids, such as BC and retinol, the relation becomes less obvious, though
there is accumulating evidence suggesting that retinol, at least in subjects with distinct
ALDH1A1/3 SNPs, exerts adverse effect.
Molecular and genetic differences may result in varying response to carotenoids.
Lifestyle and ethnicity seem to strongly modify it as well. Finally, the significance and
diagnosis of PC depends strongly on primary prevention methods. Therefore, the vast
majority of discussed studies were, in fact, more directly related to PSA than to PC itself.
Discussions for AC, zeaxanthin/lutein, and β-cryptoxanthin will not be carried out in the
present review as there are insufficient data on their effectiveness in reducing the risk of
PC to perform any comprehensive analysis.
4. Treatment and Survival in PC and Carotenoids
Apart from their influence on cancer risk prevention, carotenoids are vastly researched
in the area of cancer treatment, after the development of disease. The aim of this section
was to discuss the effects of carotenoid intake on PC treatment outcomes. In our search for
trials referring to this question, we identified 19 papers that fitted the inclusion criteria as
described in the method section. Among those, there were four clinically controlled trials,
three cohort studies, one cross-sectional study, and five case-series reports. Two studies
were nested in large randomized controlled studies (RCTs) and one was nested in a cohort
study. Apart from this, we identified six experimental animal trials that evaluated the
influence of carotenoids on PC tumor growth. Due to the lack of consistent methodology
and endpoints, we did not perform a meta-analysis of the gathered papers (Table 2).
There have been no consistent results favoring positive effects of carotenoids in PC
treatment. Moreover, it must be considered that the existence of statistically significant
outcomes in studies may not reflect the real association, but also bias, resulting from
performing additional analysis in the pursuit of positive results.
Furthermore, only one of the clinically controlled trials, carried out by Margalit et al. [48],
was of high quality—with good blinding, well-defined intervention, hard endpoint of
prostate-cancer-specific death (PCSD) and long follow up. Others in turn based their
analysis mainly on PSA changes after administration of a tomato-rich product, with no
blinding at all [49,50].
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Table 2. The summary of findings of studies which investigated the administration of carotenoids in the management of PC.
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PCSD p < 0.05 8
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PC and undergoing RT
[48]
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p >> 0.05 -
Mice that developed PC were
eligible for analysis (70% and 66%
in study 1 and 2). Additionally PC
incidence in animals receiving
LYC and control diets was
compared (p > 0.05)
[65]
1 According to the Newcastle–Ottawa Scale. 2 Among interventional group. 3 Among postsurgery patients classified as intermediate risk in the interventional group. 4 Among interventional group patients
with low (<median) increase in serum lycopene concentration (based on median change in plasma/ped blood cell concentrations). 5 Among interventional group patients with high (>median) increase
in serum lycopene concentration (based on median change in plasma/ped blood cell concentrations. 6 During trial. 7 6-years post-trial period. 8 12-years post-trial period. 9 Assessed prediagnostic daily
intake. 10 Assessed postdiagnostic daily intake. 11 Prediagnostic/postdiagnostic assessed daily lycopene intake, low<median<high. 12 For patients diagnosed with T1–T2 PC with unknown Gleason score not
included in lower risk or high-risk categories. 13 For patients diagnosed with T1–T2 or Gleason score 2–7 PC. 14 For patients diagnosed with PC characterized as T3–T4 op Gleason score 8–10, or with nodal
involvement. 15 Defined as Gleason sum ≥8 or PSA >20 ng/mL or Gleason sum ≥ 7 and clinical stage T3–T4 PC. 16 Treatment protocol consisting of: somatostatin, melatonin, retinoids solubilized in α-tocopheryl
acetate, D2R dopamine agonists, androgen inhibitors, and cyclophosphamide. Abbreviations: 13cRA—13-cis-retinoic acid; AC—α-carotene; ATBC—Alpha-Tocopherol, Beta-Carotene Cancer Prevention;
ATRA—all-trans-retinoic acid; CPS-II—Cancer Prevention Study II; BC—β-carotene; C/HRPC—castration/hormone-resistant prostate cancer; ECOG 3899—Eastern Cooperative Oncology Group 3899;
HR—hazard ratio; IFNα2b—Interferon α-2b; LYC—lycopene; PCaP—Prostate Cancer Project; PHS—Physicians’ Health Study; PC—prostate cancer; PCSD—prostate-cancer-specific deaths; PSA—prostate-specific
antigen; TC—tocopherol; TRAMP—transgenic adenocarcinoma of the mouse prostate.
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Regarding cohort studies, the one conducted by Watters et al. [52] seems to have
been well designed, with hard endpoints (PCSD), a large cohort, and well characterized
differences between participants in terms of evaluated carotenoid (BC) intake. On the
other hand Wang et al. [54] estimated LYC consumption in participants based on a self-
reported questionnaire, which may be a source of bias. At last, Venkitaraman et al. [53]
evaluated the association between PC course and carotenoid plasma concentration, which
does not necessarily reflect the actual intake of these microconstituents. The only identified
cross-sectional study, carried out by Antwi et al. [45], again relied on questionnaire-based
carotenoid intake and tissue levels.
As other papers were either case series or animal studies (Table 2.), there clearly is a
scarcity of high-quality trials evaluating the influence of carotenoids in PC.
In an RCT by Paur et al. [49], the effect of supplementing tomato-based products
standardized for LYC content on PSA change in PC patients was evaluated. Although no
effect was seen among prerandomized groups, in post-hoc analysis, a decrease in PSA
level was noted in PC patients postsurgically classified as an intermediate-risk group. This
would suggest that the outcome of an LYC intervention depends on cancer characteristics,
in line with in vitro experiments, as discussed in part I of the review [1]. Paur et al. [49]
also showed that PSA change was independently most prominent in patients with the
highest increase in LYC serum concentrations. Lack of consistency between no effect
seen in an entire intervention group and a positive outcome in subjects with the highest
increases in LYC serum concentration may be caused by the. population variability of
LYC metabolism, which is supported by research demonstrating differences in carotenoid
metabolic pathways in relation to their final biological effect (SOD, BCO etc.). Alternatively,
a higher increase in serum LYC may be associated with increased consumption of LYC-rich
food, which typically contains other biologically active substances that may act indepen-
dently, confounding results. It is important to realize that questionnaire-based trials aim
to assess the consumption of carotenoids and, in this study, in the subjects consuming
the same tomato-based product but also consuming black/green tee, pomegranate and
grape juice, soy isoflavones, selenomethionine, and n-3 fatty acids, a weaker effect on PSA
was observed.
In another interventional trial, Grainger et al. found no significant difference in
PSA slopes between PC patients receiving tomato-soy juice prior to the prostatectomy
and a control group [66]. Wang et al. [54] evaluated the effect of LYC intake on PCSD.
Although no association was found in preliminary analyses, they found fewer PCSD in a
group with high LYC intake, both based on pre- and postdiagnostic questionnaires. One
possible explanation is that such patients followed healthier lifestyle habits, including
diet, which again emphasizes the problem of confounding factors in questionnaire-based
studies. Furthermore, studies carried out by Watters et al. [52] and Margalit et al. [48]
did not indicate BC or retinol supplementation and serum concentrations to be associated
with PCSD, although both interventions lasted approximately from three up to ten years.
Antwi et al. [45] performed a vast analysis of different carotenoids, estimating daily intake
and adipose tissue concentrations and their link to the aggressiveness of disease in PC
patients. Research subjects were divided into two groups: African Americans (AAs) and
European Americans (EAs). Interestingly, the significant inverse correlation between PC
aggressiveness and β–cryptoxanthin intake was found only in AAs, whereas in EAs, such
an association was present only for LYC intake as well as LYC and AC adipose tissue
concentration. Although these results are again subject to confounding factors, they also
raise the possibility of an ethnicity specificity of the influence of carotenoids on health.
Conversely, a cohort study conducted by Venkitaraman et al. [53] found no association
between LYC, AC, BC, and retinol serum levels and time of progression, baseline PSA level,
and PSA velocity in English PC patients.
Apart from assessing their role as intervention agents in cancer treatment alone, some
attention has been drawn to the potential of employing carotenoids in combination therapy.
DiPaola et al. [51] conducted an RCT to evaluate the relative efficacy of two multidrug
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regimens in the treatment of PC, one of which included 13-cis-retinoid acid (13cRA).
However, as their work did not focus on retinoids themselves, no strong conclusion may
be drawn from their study for this review. Similarly, Di Bella et al. [59] utilized an authorial
treatment protocol including ATRA in PC management, and Pili et al. [58] reported on PC
patients treated with a combination of entinostat and cis-retinoic acid.
More conclusive results may be drawn from experimental animal testing. Among six
of the reviewed studies, two carried out by Lindshield et al. [60] and Rowles et al. [65]
did not report favorable results of carotenoid (specifically LYC) treatment. In pursuit
of the cause of this ambiguity, it is noteworthy to mention that the first study was con-
ducted on Copenhagen rats implanted with androgen-sensitive Dunning R-3327H prostatic
adenocarcinoma, while other studies (with positive results) utilized nude mice injected
with androgen-insensitive tumor (PC-3 or DU145) cells. On the other hand, Rowles et al.,
based their results on TRAMP mice experiments that spontaneously developed castration-
resistant prostate cancer (CRPC) during the LYC dietary intervention [65]. Importantly, it
was shown that animal models differ in carotenoid metabolism, which may influence the
results [67], notably the much higher BCO1 activity in mice. Alternatively, differences in
androgen sensitivity may alter carotenoid treatment outcomes. However, studies in hu-
mans, enrolling either patients with hormone-refractory or hormone-sensitive PC, have not
supported this potential difference. Four remaining animal trials reported tumor growth
inhibition induced by LYC, BC, torulene, torularhodin, and astaxanthin [61,62,64,68]. Ad-
ditionally, Tang et al. [61] presented an 38% increase in docetaxel efficacy against PC upon
addition of all-trans LYC to the regimen. The unambiguity seen between trials in animals
and humans may originate from uncontrolled environmental influence in the latter case.
This is consistent with an analysis performed by Druesne-Pecollo et al. [69], who further
suggested that the dosage of carotenoids plays an important role, with the higher dose
even being positively correlated with cancer development. For instance, carotenoids such
as canthaxanthin and astaxanthin, as well as β-apo-8′-carotenal, were shown to induce
xenobiotic metabolizing CYP1A1 and CYP1A2 enzymes in rat livers, whereas BC and
LYC had no effect [70]. On the other hand, plasma carotenoid levels were correlated with
CYP1A2 activity—positively in the case of LYC and negatively in the case of lutein [70].
Those two biological effects may point out to a complex interaction between carotenoids
and environmental exposure associated with the final outcome of carotenoids and hu-
man health and disease modulation, similar to that proposed by the CARET and ABTC
studies [71].
In conclusion, current evidence does not allow drawing conclusions regarding the
relation of carotenoids and PC prognosis. However, the aforementioned research highlights
the need for careful evaluation of differences in action of distinct carotenoids in distinct
populations and even among different patients. Furthermore, unambiguity between
studies exist, especially between humans and animal models, emphasizing the importance
of confounding factors.
5. Carotenoids and Prostatic Physiology and Pathology (Other Than PC) in
Human Studies
All the human studies identified in regard of this topic referred to the LYC. Commonly
consumed tomato products, such as tomato soup, sauce, and juice in daily servings, can
increase and prostate LYC concentrations in men with PC after three weeks of a diet rich
in tomato products [53]. While the majority of dietary LYC is typically in the all-trans
geometric configuration, tissue LYC is present primarily as cis-isomers [72].
5.1. Prostatic Hyperplasia (PH)/Benign Prostatic Hyperplasia (BPH)
Prostatic hyperplasia (PH) develops in the majority of men along with the ageing
process. Approximately 80% of men have PH at the age of 80. PH can result in urethral
obstruction and lower urinary tract symptoms. The primary cause is the increased sensitiv-
ity of the prostate to dihydrotestosterone (DHT) [73]. Moreover, inflammatory processes
may contribute to tissue injury and cytokines produced by inflammatory cells, which may
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stimulate local growth factor production and angiogenesis [74]. Drugs inhibiting DHT
production, such as finasteride, have side effects associated with antiandrogenic properties.
Consequently, new substances to combat PH are being tested.
Clinical trials are in compliance with the results from experimental studies discussed
in part I of this review [1]. In a randomized, double-blinded, placebo-controlled trial, 90
patients received either placebo or LYC-Se-SeR for three months. Prostatic biopsies were
conducted twice—at the beginning and at the end of the trial. After three months, there
was a decrease in survivin and NAIP, while caspase-3 was significantly increased in BPH
patients treated with SeR-Se-LYC, in comparison with the placebo group. This combina-
tion of compounds also reduced PSA and prostate-specific membrane antigen (PSMA)
expression [75]. It has been hypothesized that SeR, LYC, and Se, administered together,
can amplify their therapeutic efficacy also in terms of counteracting the inflammatory
component of BPH. To verify this hypothesis, a comparison experiment was conducted.
The anti-inflammatory activity of SeR, LYC, and Se on a proinflammatory phenotype in rat
peritoneal macrophages stimulated with Salmonella enteritidis lipopolysaccharide (LPS) was
compared to the effect observed in vivo in the prostate of rats with partial bladder outlet
obstruction. As expected, LPS induced a proinflammatory phenotype in macrophages.
LYC, Se, and SeR inhibited the inflammatory cascade, but it was the LYC-Se-SeR combina-
tion that caused a greater inhibitory effect on the expression of COX-2, 5-LOX, and iNOS.
The LYC-Se-SeR association was effective in reducing the loss of IκB-α, NF-κB-binding
activity, mRNA levels of TNF-α, malondialdehyde, and NO content [76]. In a multicenter
study involving nine urological Italian centers between January 2009 and December 2010,
prospectively collected data of two category of patients affected by BPH and/or PIN/ASAP
(atypical small acinar proliferation) were analyzed. In both groups, the administration
of LYC-Se-SeR (Profluss®) reduced the extension and grading of inflammation, with a
significant decrease in inflammatory cells markers such as CD3, CD8, CD20, and CD68 [77].
It is worth mentioning that there have been some clinical trials evaluating treatment
efficacy of other medical herbal preparations containing LYC. For instance, ProstateEZE
Max, an orally dosed herbal preparation containing LYC, Cucurbita pepo, Epilobium parviflo-
rum, Pygeum africanum, and Serenoa repens underwent a short-term phase II randomized
double-blind placebo controlled clinical trial. Tested as a three-month intervention for the
management of symptoms of medically diagnosed BPH in 57 otherwise healthy men aged
40–80 years, it reduced both daytime and night-time bladder emptying frequency. In the
active group, a significant reduction in the median of the validated international prostate
symptom score (IPSS) was observed [78].
5.2. Antioxidant Properties
LYC has some of the strongest antioxidant properties (in terms of quenching singlet
oxygen) of carotenoids. Compared to BC, LYC has been reported to be twice as effective
and 10-fold more active than α-tocopherol [79]. The effect of LYC supplementation on lipid
peroxidation in plasma and on DNA oxidation in prostate tissue was studied in African
American men aged 50–83 years old, recommended for prostate biopsy to detect cancer. In
a randomized, double-blind, placebo-controlled phase II clinical investigation, 131 patients
received oral doses of LYC or placebo for three weeks. Then, subjects underwent prostate
needle biopsy for the diagnosis of BPH or PC, and further two extra biopsy specimens
were obtained for measuring LYC concentration and DNA oxidation. A significant increase
in prostate LYC levels in prostate tissue due to supplementation with a tomato extract
was detected. Surprisingly, LYC supplementation did not significantly reduce the level of
biomarkers of oxidative stress (malondialdehyde and 8-oxo-2’-deoxyguanosine) [80].
In an attempt to check the impact of LYC on soluble receptors for advanced glycation
end products (sRAGE) in seminal and blood plasma, a randomized controlled trial was
carried out. The study included 15 fertile volunteers and 13 normospermic male partners
from infertile relationships. The 12-week administration of 20 mg of LYC or placebo
was followed by a crossover and treatment for a further 12 weeks. sRAGE levels were
Antioxidants 2021, 10, 319 22 of 26
determined using ELISA. LYC decreased sRAGE in seminal plasma, but not in blood
plasma. A selective local uptake of LYC in the male reproductive tract, namely in the
prostate, was suggested. Suppression of oxidative stress by LYC may explain, in part,
the putative improvement in fertility reported after LYC treatment, as reactive oxygen
species are known to oxidize sperm membrane lipids, proteins, and nucleic acids, leading
to cellular dysfunction and subsequent male infertility [81].
6. Conclusions
This review presented insight into the recent findings about the influence of carotenoids
and retinoids on prostate physiology and pathology, with special concern given to PC
and prostatic hyperplasia. A strong potential of LYC in the prevention of PC is suggested,
which seems to be increased in certain populations of men with TMPRSS2: ERG. For
other carotenoids, sufficient evidence is lacking, and only under certain situations we
may suspect an impact on PC (e.g., in smokers, BC lowers risk, while retinol increases it).
Furthermore, regarding the treatment of PC, their roles remains still uncertain.
LYC, applied alone, or in combination with Serenoa repens and Se, counteracts prostate
hyperplasia due to its proapoptotic, anti-inflammatory, antiandrogen, and antioxidant
activity. Other properties of carotenoids, although being less frequently examined, are very
promising, with a good example of astaxanthin and its apparently selective activity against
PC cells, combined with a protective effect on normal prostate epithelial cells. However, as
most studies were carried out with cell models, employing very high and nonphysiologic
concentrations, it remains to be elucidated whether similar effects may occur in vivo.
The diversity of carotenoids and their influence on the human organism and prostate in
particular still remains a source of fascinating, surprising findings. Undoubtedly, numerous
discoveries in this field are awaiting us in the following years.
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